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Background: Assessing Health-related Quality of life (HRQoL) is necessary to evaluate care and treatments provided
to patients with major depressive disorder (MDD), in addition to the traditional assessment of clinical outcomes.
However, HRQoL remains under-utilized to assess the effectiveness of repetitive transcranial magnetic stimulation
(rTMS) in research or in a routine clinical setting. The primary objective of this exploratory study on MDD was to
investigate the impact of low-frequency rTMS on HRQoL using the SF-36 questionnaire. A secondary objective was
to study the functional neural substrate underlying HRQoL changes using neuroimaging.
Methods: Fifteen right-handed patients who met DSM-IV criteria for MDD participated in the study. HRQoL was
assessed using the SF-36, and regional cerebral blood (rCBF) flow using 99mTc-ECD-SPECT. Voxel based correlation
was searched between concomitant changes in rCBF and in HRQoL after rTMS.
Results: Role-Physical Problems dimension showed a statistical significant improvement of 73.2% (p = 0.001) and an
effect size (Cohen’s d) of 0.43, indicating moderate effect. Five SF-36 dimension scores and the two composite
scores showed effect sizes ranged from 0.28 to 0.43. Improvement of Mental Composite Score (MCS)-SF-36 after
rTMS was correlated with a concomitant decrease of precuneus perfusion (p < 0.001). Post-hoc analyses confirmed
that decreased perfusion in precuneus was correlated with improvement of HRQoL, especially for MCS (r =−0.71;
p < 0.001), Mental Health (r =−0.81; p < 0.001) and Social Functioning (r =−0.57; p = 0.026) dimensions.
Conclusions: This study suggests low-frequency rTMS can improve HRQoL, through its role-physical problems
dimension, in patients with MDD. This improvement is associated with a decreased perfusion of the precuneus,
a brain area involved in self-focus and self-processing, arguing for a neural substrate to the impact of rTMS
on HRQoL.
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Major depressive disorder (MDD) [1] remains one of the
leading causes of disability in developed countries des-
pite pharmacological and psychological treatments [2]. A
new alternative for depressed individuals is repetitive
transcranial magnetic stimulation (rTMS), a non-
invasive well-tolerated technique [3-5]. rTMS protocols
have been developed using high-frequency stimulation
(> 5 Hz) of the left dorsolateral prefrontal cortex
(DLPFC) or low-frequency (< 1 Hz) of the right DLPFC.
The choice of distinct frequency comes from electro-
physiological data of the motor cortex, showing that
high-frequencies may have an excitatory effect while low-
frequencies tend to suppress cortical excitability [6,7].
Effectiveness of rTMS has been investigated in most stud-
ies using clinical outcomes, such as change in depressive
symptomatology [8,9]. Thereby, meta-analyses have high-
lighted a threshold of 50% decrease in symptom severity,
in up to 76% of patients [10-12]. Interestingly, the effi-
ciency of low-frequency rTMS stimulation of the right
DLPFC and of high-frequency rTMS stimulation of the
left DLPFC seems to be similar in depressed patients
[11,13,14].
On the other hand, Health-related Quality of life
(HRQoL) questionnaires are considered valuable and ne-
cessary tools to evaluate care and treatments provided to
patients with MDD, in addition to the traditional assess-
ment of clinical outcomes [15-17]. HRQoL may add
interesting information that is oriented toward a more
global service to individuals including the subjective ex-
perience of their illness, with regard to their symptoms
but also their functioning embedded in social and envir-
onmental context [15]. However, HRQoL remains under-
utilized to assess the effectiveness of rTMS in research or
in a routine clinical setting [8], and more globally in psy-
chiatric clinical practice [18,19]. In congruence with prior
investigations on HRQoL in MDD following antidepres-
sant pharmacotherapy [20,21], only two recent studies,
using the World Health Organization's Quality of Life
Measure , brief version (WHOQOL BREF) [22] and the
Medical Outcome Study 36-item Short Form (SF-36)
[23,24] questionnaires, have shown improvement in
HRQoL domains following high-frequency rTMS [8,25].
These important findings should be confirmed using
low-frequency rTMS which is better tolerated than high-
frequency rTMS in terms of seizure risk [26].
The primary objective of this exploratory study was to
investigate the impact of low-frequency rTMS on
HRQoL using the SF-36 questionnaire, in patients with
MDD. In addition, a better understanding of the mech-
anism underlying HRQoL changes is of particular inter-
est in depression, as already proposed in schizophrenia
[27,28]. A secondary objective was thus to study the
functional neural substrate underlying HRQoL changesusing neuroimaging with 99 m Tc-ethyl cysteinate dimer
single-photon emission computed tomography (99mTc-
ECD-SPECT), a valuable tool to investigate the regional
cerebral blood flow (rCBF), in a range of psychiatric dis-
orders such as depression [29-31].
Methods
Patients
Fifteen right-handed patients, who met DSM-IV criteria
for MDD participated in the study [1]. Inclusion criteria
were: unipolar depression, Beck Depression Inventory-II
(BDI-II) score ≥ 20 [32], non-response to pharmaco-
logical treatment using a minimum of two distinctly dif-
ferent classes of antidepressant medications for episodes
occurring at the time of enrolment, and written informed
consent. Exclusion criteria were based on the following
criteria: age under 18 years, MDD with psychotic fea-
tures, psychiatric diagnosis other than MDD on Axis I of
DSM-IV-TR [1], neurological disorders or convulsive dis-
orders, and previous rTMS or electroconvulsive therapy
treatments. Pretreatment with an antidepressant and/or
mood stabilizer medication had to be stable for at least
4 weeks prior to entry in the study and remain un-
changed throughout. The local Ethics Committee,
Marseille, France approved the investigations. The pro-
ject was conducted in accordance with the declaration of
Helsinki and French Good Clinical Practice [33,34].
rTMS treatment
Low-frequency magnetic stimulation was performed
using a figure eight-shaped water-cooled coil (Medtronic
Inc., Minneapolis, MN, USA) to the right DLPFC. At the
first rTMS session, the motor threshold was defined as
the minimum intensity leading to the most prominent
abduction of the left abductor pollicis brevis muscle after
stimulation of the right motor cortex. This movement
was determined by an electromyogram recording. Dur-
ing the treatment, the coil was positioned 5 cm anterior
and in a parasagittal line from the motor cortex. rTMS
was delivered with following characteristics: six 60-s
trains at 1 Hz and at 120% of the motor threshold were
applied in each session with a 30-s interval between the
trains. Twenty treatment sessions were administered
during 4 weeks (total pulses, 7200) [11].
Data collection
The following data were recorded: (1) demographic
characteristics: gender and age, marital status and educa-
tion level; (2) handedness determined by the Edinburgh
Inventory [35]; (3) clinical characteristics: duration of ill-
ness, episode duration; (4) depression severity was
assessed using the 21-item self-report Beck Depression
Inventory (BDI-II) [32]. A score from 0 to 63 is calcu-
lated, with higher scores indicating more severe
Dumas et al. Health and Quality of Life Outcomes 2012, 10:87 Page 3 of 7
http://www.hqlo.com/content/10/1/87depressive symptoms; (5) HRQoL was assessed using the
SF-36 [23,24]. SF-36 is a generic, self-administered, and
worldwide-used questionnaire consisting of 36 items de-
scribing 8 dimensions: Physical Functioning (PF), Social
Functioning (SF), Role-Physical Problems (RPP), Role-
Emotional Problems (REP), Mental Health (MH), Vitality
(VIT), Bodily Pain (BP), and General Health (GH). Each di-
mension is scored within a range of 0 (low HRQoL level)
to 100 (high HRQoL level). Two component summary
measures of SF-36, namely physical and mental composite
scores (PCS-SF-36 and MCS-SF-36) are calculated.
Depression severity and HRQoL were assessed at base-
line (t0), and at the end of rTMS (t1).
SPECT protocol and analysis
Brain SPECT was performed in all patients, with the
same camera, and under the same conditions, as previ-
ously described [29]. This exam was performed during
the week before rTMS, and a second SPECT scan was
obtained during the week after the end of the rTMS
treatment. A voxel-by-voxel group study was then per-
formed using Statistical Parametric Mapping (SPM) 8
(Wellcome Department of Cognitive Neurology, Univer-
sity College, London), running on Matlab (Mathwork-
sInc, Sherborn, MA).
Images were initially converted from the DICOM to
the Analyze format using MRIcro (www.mricro.com),
and transferred to SPM8. Data were then standardized
with the Montreal Neurological Institute atlas, using a
12-parameter affine transformation, followed by non-
linear transformations and trilinear interpolation. Dimen-
sions of resulting voxels were 2x2x2 mm. Standardized
data were then smoothed with a Gaussian filter
(FWHM=12 mm), to blur individual variations in gyral
anatomy, and to increase signal-to-noise ratio. The “pro-
portional scaling” routine was used to control for individ-
ual variation in global brain perfusion.
Voxel based correlation was searched between con-
comitant changes in rCBF and in HRQoL after rTMS
(PCS- and MCS-SF-36 changes). For this, brain SPECT,
PCS and MCS baseline scores were subtracted with their
respective post rTMS scores, and then divided by their
respective baseline scores. The SPM (T) maps were
obtained at a height threshold of p < 0.001 (uncorrected)
for the voxel, with at least 24 voxels within each cluster
(forth FWHM of the Gaussian filter).
Statistical analysis
Data were expressed in proportion or mean and stand-
ard deviation (SD). Pre-post rTMS HRQoL comparisons
were analyzed using two-tailed paired t-tests. Cohen's d
effect sizes were then calculated [8,36]. As recom-
mended, we considered d values from 0.15 to 0.39, 0.4
to 0.74 and from 0.74 to 1.1 as indicating small,moderate and large effect sizes, respectively [8,36]. Asso-
ciations were then looked for between cluster(s) previ-
ously found correlated with PCS- and/or MCS-SF-36,
and changes in dimensions of SF-36 and BDI-II, using
Spearman’s correlation tests. Spearman’s correlation tests
were used to determine the relationship between
changes in BDI-II score and changes in dimensions and
scores of SF-36. All the tests were two-sided. Statistical
significance was defined at p < 0.05. Statistical analysis
was performed using the SPSS version 17.0 software
package (SPSS Inc, Chicago, IL).
Results
Patient characteristics
The fifteen subjects (twelve women) presented pharma-
coresistant unipolar depression with high severity (BDI-
II = 36; SD= 9.8). The average patient age was 49.8 years
(SD= 10.5), the duration of illness was 14.4 years (SD=
10.1), and the duration of current depressive episode
was 38.2 months (SD= 35.1). Twelve patients were single
or divorced; ten patients had a high school or college
education. Most patients (n = 13) received rTMS as add-
on treatment, and were treated under antidepressant
monotherapy (n = 10), or combination of antidepressant
and mood stabilizer (n = 3). Nine patients took benzodia-
zepines or hypnotics during rTMS treatment. Two
patients were totally medication-free.
Quality of life
PCS showed improvement of 5.1%, MCS of 13.9%, and
BDI-II of 13.1%. Role-Physical Problems dimension
showed a statistically significant improvement of 73.2%
(p = 0.001) and an effect size (Cohen’s d) of 0.43, indicat-
ing moderate effect. General Health dimension remained
fairly constant (2% increase), although the other dimen-
sions increased from 11 (Social functioning) to 100%
(Role-Emotional Problems). Five SF-36 dimension scores
(Physical Functioning, Role-Emotional Problems, Mental
Health, Bodily Pain, Vitality) and the two composite
scores showed small to moderate effect sizes (Table 1 ).
Significant correlations between BDI-II changes and
HRQoL were found for the following dimensions: MCS
(r =−0.71; p = 0.003), MH (r =−0.65; p = 0.009), SF
(r =−0.58; p = 0.023), VIT (r =−0.75; p = 0.001), PF
(r =−0.56; p = 0.03) and GH (r =−0.52; p = 0.04).
Correlation between brain SPECT perfusion and HRQOL
and clinical scores after rTMS
HRQoL improvement for MCS-SF-36 was associated
with a decreased perfusion of the precuneus (p < 0.001,
uncorrected; T-score = 3.85) (Figure 1). No other signifi-
cant correlation was found using whole brain analysis, in
particular for PCS-SF-36 and for BDI-II.
Table 1 Pre-post rTMS HRQoL comparisons (n = 15)
SF-36 Pre-rTMS Post-rTMS P value Effect size (ES)
Mean (SD) Mean (SD) (Cohen's d)
PF 53.3 (25.4) 62.0 (28.5) 0.193 + 0.32 a
RPP 18.3 (30.6) 31.7 (32.0) 0.001 + 0.43 b
VIT 19.3 (15.1) 25.0 (17.1) 0.270 + 0.35 a
BP 40.9 (21.2) 49.9 (28.7) 0.125 + 0.36 a
MH 25.6 (12.0) 32.8 (22.8) 0.247 + 0.39 a
REP 13.3 (24.6) 26.7 (36.1) 0.159 + 0.43 b
SF 29.2 (21.0) 32.5 (25.4) 0.638 + 0.14
GH 28.6 (21.1) 29.1 (19.5) 0.937 + 0.02
MCS 23.7 (6.8) 27 (12) 0.109 + 0.31 a
PCS 38.9 (8.1) 40.9 (9.2) 0.177 + 0.28 a
SF-36—PF Physical Functioning, RPP Role—Physical Problems, VIT Vitality, BP
Bodily Pain, MH Mental Health, REP Role—Emotional Problems, SF Social
Functioning, GH General Health, MCS Mental Composite Score, PCS Physical
Composite Score.
a small effect size; b moderate effect size.
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this cluster and the SF-36 dimension and BDI-II scores
(Table 2). rCBF decrease of the precuneus was highly
correlated with an HRQoL dimension increase of MCS-
SF-36 (r =−0.71; p < 0.001), MH (r =−0.81; p < 0.001) and
SF (r =−0.57; p = 0.026). On the contrary, precuneus per-
fusion was not significantly correlated with other SF-36
dimensions or with BDI-II score (p > 0.05).
Discussion
Our study provides important information on the impact
of rTMS on HRQoL in patients with MDD. Firstly, using
a low-frequency rTMS administered on the right DLPFC,
our findings tend to confirm the preliminary results of
Berlim et al.[8], and Hadley et al.[25] using a high-
frequency rTMS on the left DLPFC. Role-Physical Pro-
blems dimension improved significantly from baseline
and showed moderate effect size. Five SF-36 dimension
scores and the two composite scores showed effect sizesFigure 1 Anatomical localization of areas of decreased perfusion afte
(p < 0.001, uncorrected; k > 24).higher than 0.28, suggesting a small to moderate “clinic-
ally” meaningful improvement of HRQoL. Although the
HRQoL increase in our study showed less magnitude on
physical, psychological and overall domains (respective
Cohen’s d, 0.44, 0.44, 0.57) than those found in Berlim’s
study [8] and on physical functioning, vitality, social
functioning and mental health dimensions than in Had-
ley’s study [25], precaution should be taken in this com-
parison. This difference may be explained by a higher
effect of high-frequency rTMS on HRQoL than low-
frequency rTMS. However, the study of Berlim et al. did
not use the same questionnaire, and the SF-36 and
WHOQOL-BREF appear to measure distinct concepts
related to HRQoL [37]. Concerning the study of Hadley
et al., the baseline HRQoL levels were significantly higher
than in our sample, and differential change in means
from baseline may simply be due to skewness interacting
with baseline differences [38]. Future studies should thus
compare the impact of high and low-frequency rTMS on
HRQoL using both questionnaires.
Moreover, this whole-brain voxel-based study is the first
to investigate the neural substrate underlying HRQoL
changes in patients with MDD treated by rTMS. We show
that improvement of HRQoL for social and mental health
dimensions SF-36-scores after rTMS is associated with a
decreased perfusion of the precuneus. The precuneus has
reciprocal connections with the DLPFC [39]. So, the
decreased activity of the precuneus can result from the in-
hibitory effects of low-frequency rTMS over the right
DLPFC, which can induce activity changes in distant brain
regions via the neural pathways [40].
This report strengthens the scientific conceptual basis
of HRQoL. The psychosocial construct of HRQoL,
which required accurate self-assessment by individuals
of their own inner feelings and state of well-being,
appears consistent with precuneus involvement [31]. In-
deed, precuneus has been mainly implicated in subject-
ive experience and conscious self-representation [31,41].
In healthy subjects, precuneus is activated in self-relatedr rTMS correlated with concomitant HRQoL improvement
Table 2 Correlations between changes in rCBF within the
precuneus and changes in SF-36 dimensions and BDI-II
Precuneus cluster R# p values
SF-36
PF - 0.25 0.380
RPP 0.04 0.881
VIT - 0.10 0.712
BP 0.23 0.410
MH - 0.81 < 0.001
REP - 0.37 0.179
SF - 0.57 0.026
GH - 0.10 0.712
MCS - 0.71 < 0.001
PCS 0.37 0.173
BDI-II 0.46 0.087
# R: Spearman’s correlation coefficient.
SF-36—PF Physical Functioning, RPP Role—Physical Problems, VIT Vitality, BP
Bodily Pain, MH Mental Health, REP Role—Emotional Problems, SF Social
Functioning, GH General Health, MCS Mental Composite Score, PCS Physical
Composite Score.
BDI-II. Beck Depression Inventory - II.
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mode network [39], and during tasks about reflection on
one’s own personality traits and physical appearance
[42]. Precuneus has been also involved in the subjective
well-being and distress of patients with post-traumatic
stress disorder [43].
Our findings attempt to provide some clues for a better
understanding of the mechanism underlying the relation-
ship between depression and HRQoL found in previous
studies [15,44,45]. Indeed, patients with depression suffer
from an increased self-focus (i.e. link negative affect and
episodic memory deficit with an increased attention to
the self ) [46], and exaggerated self-processing (i.e. the ap-
praisal of stimuli as strongly related to one’s own person)
[47]. Exaggerated self-referential processing (SRP) espe-
cially distorts interpretations of social cues and maintains
social fears because of maladaptive cognitions regarding
self (i.e. as socially incompetent) and others (i.e. as crit-
ical judges) [48]. Decreased activation in the precuneus
could thus reflect a restored deactivation of the default
mode network [49]. We hypothesize that decreased rCBF
of the precuneus may be associated to a reduction of SRP
allowing patients to focus their own attention on their
environment, relatives and friends and then explaining
an improvement of HRQoL. On the other hand, precu-
neus has been also involved in the theory of mind (ToM)
[50,51] which is conceived as a set of abilities that enable
humans to understand other peoples' mental states and
intentions. In particular, ToM is interrelated with self-focus
attention and self-emotional awareness [51]. Moreover,
previous studies have reported that ToM performance wasassociated with an increased perfusion of the precuneus
[28,31]. Interestingly, Wolkenstein et al. [52] found that
depressed patients were more accurate in decoding nega-
tive than neutral and positive mental states. The precu-
neus hypoperfusion found in our study may reflect a
better attention for positive episodes and a decreased
emotional response to negative thoughts [43] and thus
be associated with improved mental health HRQoL con-
cerning feelings of nervousness, peacefulness, and happi-
ness [28,31].
Our findings should be considered in treatment of
patients with MDD, supporting the use of therapeutic inter-
ventions targeting self-focus and SRP, such as mindfulness-
based cognitive therapy [53] or cognitive base-therapy, to
improve HRQoL. On the other hand, the impact of rTMS
applied specifically to precuneus in patients with MDD on
HRQoL should be investigated in future studies.
Lastly, the links between precuneus perfusion and
HRQoL on the one hand, and those between HRQoL
and depression on the other hand, help to better under-
stand the mechanism of action of rTMS. The impact of
rTMS may not only relieve the symptoms of MDD, but
also affects other relevant psychosocial domains mea-
sured by HRQoL, which may in turn influence mood
improvement. In accordance with this hypothesis, recent
studies have shown HRQoL to be a prognostic factor
associated with clinical outcome in various chronic dis-
eases [54,55]. These findings may provide a support to
integrate HRQoL in clinical practice, as complementary
information to that traditionally collected in psychiatry.
Limitations
Several limitations have to be considered in this explora-
tory study. The first limitation is the small sample size
(n = 15); the lack of power may explain the contrast be-
tween the non-significant statistical results and the small
to moderate level of effect sizes. Second, the absence of
control group limits our ability to attribute the HRQoL
changes exclusively to rTMS. However, although con-
trolled trials are appropriate for establishing potentially
causal associations, more naturalistic studies have the
advantage of assessing “real life” situations of patients
under treatment. These distinct limitations, also present
in the previous reports [8,25], should be considered in
future studies. Third, we used the standard 5-cm
localization procedure for applying rTMS over the right
DLPFC, instead of using a neuronavigational method,
which seems to enhance response to rTMS [56]. Fourth,
the unbalanced sample regarding gender might have bias
our findings. However, the influence of gender on
HRQoL is still unclear [57-59], and gender is not asso-
ciated with difference in rTMS outcomes [60]. Sixth,
some patients were receiving medical treatment during
the study, including benzodiazepins that modify cortical
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on HRQoL and rCBF cannot be excluded. Finally, the
use a self-rating subjective scale (BDI-II) to assess the
severity of depression could be criticized. However, stud-
ies support a satisfactory convergent validity between
BDI-II and Hamilton Depression Rating Scale or Clinical
Global Impression [61,62].
Conclusion
This study suggests low-frequency rTMS can improve
HRQoL, through its role-physical problems dimension,
in patients with MDD. This improvement is associated
with a decreased perfusion of the precuneus, a brain area
involved in self-focus and self-processing, arguing for a
neural substrate to the impact of rTMS on HRQoL.
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